Over two years ago, the federal government announced that the rules governing the pricing of pharmaceuticals in Canada were changing. Now, after a lengthy public consultation process with interested Canadians and stakeholders, including the pharmaceutical industry, the Government of Canada has announced the final amendments to the Patented Medicines Regulations aimed at saving “Canadians billions over the next decade.”
The Patented Medicine Prices Review Board (PMPRB) has introduced the following amendments:
In setting drug prices, a “basket” of 11 other countries (no longer including the US and Switzerland), that are similar to Canada’s population, economy and approach […]
